Mazdutide
Research PhaseMazdutide (IBI362)
- Category
- Weight Loss & Metabolism
- Aliases
- IBI362
- Administration
- Subcutaneous injection
Documented side effects
Tier 1 · Peer-reviewed / regulatoryGI symptoms (most common)
Nausea, vomiting, or diarrhea are the most frequently reported effects, especially when starting or increasing the dose.
Nausea (common, especially early doses)
Nausea is frequently reported, particularly during the initial loading phase.
Injection site reactions
Mild redness, swelling, or discomfort at the site of injection.